184 related articles for article (PubMed ID: 29665439)
21. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
Park J; Park SY; Kim JH
Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
23. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
25. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate.
Lee MS; Lee JE; Byun E; Kim NW; Lee K; Lee H; Sim SJ; Lee DS; Jeong JH
J Control Release; 2014 Oct; 192():122-30. PubMed ID: 24995950
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
27. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
28. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
29. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
31. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.
Choi KM; Jang M; Kim JH; Ahn HJ
Biomaterials; 2014 Aug; 35(25):7121-32. PubMed ID: 24854094
[TBL] [Abstract][Full Text] [Related]
32. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
33. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.
Li Y; Zhang J; Wang B; Shen Y; Ouahab A
Drug Dev Ind Pharm; 2016; 42(5):737-46. PubMed ID: 26472259
[TBL] [Abstract][Full Text] [Related]
35. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
36. Silencing of twist expression by RNA interference suppresses epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer.
Wang WS; Yang XS; Xia M; Jiang HY; Hou JQ
Asian Pac J Cancer Prev; 2012; 13(9):4435-9. PubMed ID: 23167357
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
Mattheolabakis G; Ling D; Ahmad G; Amiji M
Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
[TBL] [Abstract][Full Text] [Related]
38. Mesoporous silica nanoparticles functionalized with hyaluronic acid. Effect of the biopolymer chain length on cell internalization.
Nairi V; Magnolia S; Piludu M; Nieddu M; Caria CA; Sogos V; Vallet-Regì M; Monduzzi M; Salis A
Colloids Surf B Biointerfaces; 2018 Aug; 168():50-59. PubMed ID: 29456044
[TBL] [Abstract][Full Text] [Related]
39. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.
Zhu X; Shen H; Yin X; Long L; Xie C; Liu Y; Hui L; Lin X; Fang Y; Cao Y; Xu Y; Li M; Xu W; Li Y
Oncogene; 2016 Jan; 35(3):323-32. PubMed ID: 25867064
[TBL] [Abstract][Full Text] [Related]
40. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
